Cantor Fitzgerald initiated coverage on ARQT with an Overweight rating and a $48 target, citing Zoryve's strong growth and expansion potential in dermatology. The firm projects peak Zoryve sales of $2.6–$3.5 billion, supported by U.S./Canada market presence and new indications, including infants and hidradenitis suppurativa. The positive stance could drive multiple expansion and upside for ARQT over the coming years.
Health Canada approved ARQT's Zoryve cream for atopic dermatitis. 90% of patients showed symptom improvement in clinical trials. ARQT's stock rose 42% recently, closing at $17.29. Current RSI value for ARQT is 71, indicating overbought conditions. Tnxp Pharmaceuticals has also shown significant stock movement recently.
Arcutis Biotherapeutics has RSI near 28, indicating potential for short-term gains. ZORYVE Foam approved in Canada, may boost ARQT's market position. ARQT shares fell 14% recently, reflecting current market volatility. 80% of patients achieved treatment success with ZORYVE in trials. Oversold status may present buying opportunity for ARQT investors.
